# China NMPA Drug Inspection - Shanxi Taiyuan Pharmaceutical Co., Ltd. (formerly Taiyuan Pharmaceutical Factory) - Norfloxacin capsules

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/shanxi-taiyuan-pharmaceutical-co-ltd-formerly-taiyuan-pharmaceutical-factory/dfce698d-43e8-409f-8c83-519eb7eae65f/
Source feed: China

> China NMPA drug inspection for Shanxi Taiyuan Pharmaceutical Co., Ltd. (formerly Taiyuan Pharmaceutical Factory) published September 29, 2020. Drug: Norfloxacin capsules. The Shaanxi Provincial Drug Administration released Bulletin Issue 9 of 2020 on September 29, 2020, following a series o

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Shaanxi Province Drug Quality Bulletin (Issue 9, 2020, Serial No. 19)
- Company Name: Shanxi Taiyuan Pharmaceutical Co., Ltd. (formerly Taiyuan Pharmaceutical Factory)
- Publication Date: 2020-09-29
- Drug Name: Norfloxacin capsules
- Inspection Finding: The item that fails to meet the requirements is the "Inspection" section.
- Action Taken: The relevant municipal (county, district) drug regulatory authorities have taken necessary control measures and are investigating and handling the matter in accordance with relevant laws and regulations.
- Summary: The Shaanxi Provincial Drug Administration released Bulletin Issue 9 of 2020 on September 29, 2020, following a series of drug sampling inspections aimed at ensuring public medication safety. The report identifies five batches of drugs that failed to meet national quality standards. The manufacturers involved include Anhui Hongxin Pharmaceutical Development Co., Ltd., Anhui Bozhou Qiancao Guoyao Co., Ltd., Ningxian Kangshengyuan Pharmaceutical Co., Ltd., Qingyang Yixiang Pharmaceutical Co., Ltd., and Shanxi Taiyuan Pharmaceutical Co., Ltd. The specific products cited for non-compliance include Salted Plantago Seed, Roasted Malt, Polygonum multiflorum vine, Salt-processed Eucommia, and Norfloxacin Capsules. The main violations were identified based on the 2015 Edition of the Chinese Pharmacopoeia. Issues ranged from physical appearance and properties to more critical failures in content determination and general inspection requirements. These deviations indicate that the products did not meet the required chemical or physical profiles established for safe use. In response to these findings, the provincial administration has directed municipal and district drug regulatory departments to implement immediate control measures. These actions include securing the non-compliant batches and launching formal investigations into the responsible units. The authorities are currently handling these cases in accordance with relevant pharmaceutical laws and regulations to rectify the quality issues and mitigate risks to public health.

Company: https://www.globalkeysolutions.net/companies/shanxi-taiyuan-pharmaceutical-co-ltd-formerly-taiyuan-pharmaceutical-factory/2527ab38-b882-4eea-99cc-3234103434f0/